This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric patients three years and older with acute ...

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

Hepatitis C virus (HCV) infection is highly associated with the development of metabolic dysfunction-associated steatotic ...

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

The Hepatitis C Elimination Coalition commends Senators Bill Cassidy (R-LA) and Chris Van Hollen (D-MD) for their bipartisan ...

The HIV/HBV/HCV test kits market plays a vital role in the global fight against infectious diseases. These diagnostic tools are crucial for early detection and effective treatment of HIV, hepatitis B ...

Discover a study where figures indicate a substantial drop-off following diagnosis, undermining efforts to eliminate HCV in ...

Patients infected with Hepatitis C Virus (HCV) often present with rheumatic symptoms, but its link to rheumatoid arthritis ...

Six patients were found to have hepatitis C viremia ... The anesthesiology assistant contracted HCV from Patient 1 and subsequently transmitted the virus, during the incubation stage of his ...

Shares of AbbVie (ABBV) traded over 1% higher on Wednesday after the company announced that the U.S. Food and Drug ...